Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.
about
Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathwayTargeted approaches to induce immune tolerance for Pompe disease therapyModelling clinical systemic lupus erythematosus: similarities, differences and success storiesPathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusVNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicryBtk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune DiseasesAutoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells.Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy.NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.Increase of MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes.Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.
P2860
Q26746697-928E3F16-073E-47B3-A25C-A343C2FE072CQ26767363-149FA6DD-6682-4DD1-8CCB-824444DD491FQ28074217-74320BB4-CEEB-4028-9B42-638D28A15065Q28088753-611CA4D2-D887-4ABF-B3C2-D77BD909D817Q33688370-ABCB139E-E805-4F0F-BE72-67B71D6BF3DFQ37730801-1C08C928-8053-4EB5-9154-CE9B65A7A114Q39109245-3BEE4F59-EE7D-4062-B339-B8382A73D004Q40110864-9A4F689F-2C02-4559-B41C-23A451E0EA94Q46126518-AF528D53-85AA-4974-9BA4-9DD8A94A71C6Q47621604-449AAEAE-24F0-448E-AD75-680FD5A0CCCEQ48250996-83AD3FF7-637C-4C1D-9416-2F9973BF42C4Q49192001-61B6C313-7ABB-4413-8A40-AA539FAC0F29Q49593848-41784B50-81B5-4002-BF43-1872EFAECF3D
P2860
Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@ast
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@en
type
label
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@ast
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@en
prefLabel
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@ast
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@en
P2093
P2860
P356
P1476
Dual B cell immunotherapy is s ...... ntaneous or accelerated lupus.
@en
P2093
Ali A Zarrin
Allen Nguyen
Dhaya Seshasayee
Flavius Martin
Laura DeForge
Mercedesz Balazs
Sami McVay
Wyne P Lee
P2860
P304
P356
10.1002/ART.38907
P577
2015-01-01T00:00:00Z